First in Man Trial with the drug eluting absorbable metal scaffold. To assess safety
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
46
Middelheim Hospital
Antwerp, Belgium
Universitätsklinik Essen, Westdeutsches Herzzentrum
Essen, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Lukaskrankenhaus Neuss
Neuss, Germany
Target Lesion Failure
Time frame: 6 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Catharina Ziekenhuis
Eindhoven, Netherlands
Luzerner Kantonsspital
Lucerne, Switzerland